APAC Syndromic Multiplex Diagnostic Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143433
- Pages: 225
-
Format:
Short Description
Asia-Pacific Syndromic Multiplex Diagnostic Market - By Product and Services (Reagents & Consumables, Instruments, Software & Accessories and Services), Infection type (Viral, Bacterial, Parasites and Fungal), Disease (Respiratory Infections, Gastroenteritis, Sexually Transmitted Infections, Sepsis, Meningitis and Others), Panels Type (Respiratory Panel, GI-Enteric Panel, SexuallyTransmitted Disease Panel, Blood-Sepsis Panel, Meningitis panel and Others), End User (Clinical Laboratories, Hospitals, Pharmaceutical & Biotechnology Companies, Research Institutes and Others), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippine, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition:
Syndromic multiplex diagnostic is a type of advanced diagnostic test that is utilised to detect various types of infection diseases such as respiratory infection, infective gastroenteritis, sexually transmitted infections, sepsis, and meningitis, among other types of infectious diseases. Syndromic multiplex diagnostic also helps the clinicians or hospitals to detect the symptoms and signs of the various types of diseases. This lets the health care providers provide the right treatment for the patients and offer more precise outcomes and care that can be performed more quickly.
Market Segmentation:
The Asia-Pacific syndromic multiplex diagnostic market is categorized into five segments: products and services, infection type, disease, panels type, and end user.
Based on products and services, the Asia-Pacific syndromic multiplex diagnostic market is segmented into reagents & consumables, instruments, software & accessories and services
Based on infection type, the Asia-Pacific syndromic multiplex diagnostic market is segmented into viral, bacterial, parasites and fungal
Based on disease, the Asia-Pacific syndromic multiplex diagnostic market is segmented into respiratory infections, gastroenteritis, sexually transmitted infections, sepsis meningitis and others
Based on panels type, the Asia-Pacific syndromic multiplex diagnostic market is segmented into respiratory panel, GI-enteric panel, sexually transmitted disease panel, blood-sepsis panel, meningitis panel and others
Based on end user, the Asia-Pacific syndromic multiplex diagnostic market is segmented into clinical laboratories, hospitals, pharmaceutical & biotechnology companies, research institutes and others
Market Players
The major companies which are dealing in the Asia-Pacific syndromic multiplex diagnostic are listed below:
BioFire Diagnostics (A Subsidiary of bioMrieux SA)
Seegene Inc.
Luminex Corporation. A DiaSorin Company
F. Hoffmann-La Roche Ltd
BD
Bio-Rad Laboratories, Inc.
Cepheid (A Subsidiary of Danaher)
QIAGEN
Abbott
Hologic, Inc.
Thermo Fisher Scientific Inc.
Siemens Healthcare GmbH
Biocartis
QuantuMDx Group Ltd.
Prominex Inc.
Curetis (A Subsidiary of OpGen, Inc.)
MiRXES Pte Ltd.
TABLE OF CONTENTS
1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.3 OVERVIEW OF ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET 27
1.4 LIMITATIONS 29
1.5 MARKETS COVERED 29
2 MARKET SEGMENTATION 32
2.1 MARKETS COVERED 32
2.2 GEOGRAPHICAL SCOPE 33
2.3 YEARS CONSIDERED FOR THE STUDY 34
2.4 CURRENCY AND PRICING 34
2.5 DBMR TRIPOD DATA VALIDATION MODEL 35
2.6 MULTIVARIATE MODELLING 38
2.7 PRODUCT AND SERVICES LIFELINE CURVE 38
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 39
2.9 DBMR MARKET POSITION GRID 40
2.10 MARKET END USER COVERAGE GRID 41
2.11 VENDOR SHARE ANALYSIS 42
2.12 SECONDARY SOURCES 43
2.13 ASSUMPTIONS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 46
4.1 PESTEL ANALYSIS 48
4.2 PORTER'S FIVE FORCES 49
4.3 MARKET SHARE PER PANEL, FOR TOP 3 PLAYERS (2021) 50
5 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: REGULATIONS 51
6 MARKET OVERVIEW 54
6.1 DRIVERS 56
6.1.1 RISING PREVALENCE OF INFECTIOUS DISEASES 56
6.1.2 RISING ADOPTION OF MOLECULAR DIAGNOSTICS TECHNIQUES 57
6.1.3 INCREASING REGULATORY APPROVAL FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) TESTING 58
6.1.4 INCREASING DEMAND FOR FAST AND ACCURATE DIAGNOSTIC RESULTS 58
6.2 RESTRAINTS 59
6.2.1 HIGH COST OF DIAGNOSTIC PRODUCTS 59
6.2.2 EXPLICIT LIMITATION OF SYNDROMIC MULTIPLEX DIAGNOSTIC 59
6.3 OPPORTUNITIES 60
6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 60
6.3.2 RISING DIAGNOSTIC HEALTHCARE EXPENDITURE 60
6.3.3 INTRODUCTION OF TECHNOLOGICAL ADVANCED PRODUCTS 62
6.4 CHALLENGES 63
6.4.1 PRODUCT RECALLS 63
6.4.2 LACK OF SKILLED PROFESSIONALS AND BARRIERS FACED IN CONDUCTING DIAGNOSTIC TESTS 63
7 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PRODUCT & SERVICES 64
7.1 OVERVIEW 65
7.2 REAGENTS & CONSUMABLES 68
7.3 INSTRUMENTS, SOFTWARE & ACCESSORIES 68
7.4 SERVICES 69
8 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY INFECTION TYPE 71
8.1 OVERVIEW 72
8.2 VIRAL 75
8.2.1 CORONAVIRUS 76
8.2.2 INFLUENZA VIRUS 76
8.2.3 ADENOVIRUS 76
8.2.4 RHINOVIRUS 76
8.2.5 ROTAVIRUS 76
8.2.6 OTHERS 76
8.3 BACTERIAL 77
8.3.1 PNEUMONIAE 78
8.3.2 BORDETELLA PERTUSSIS 78
8.3.3 STAPHYLOCOCCUS 78
8.3.4 OTHERS 78
8.4 PARASITES 78
8.5 FUNGAL 79
9 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY DISEASE 81
9.1 OVERVIEW 82
9.2 RESPIRATORY INFECTIONS 85
9.3 GASTROENTERITIS 86
9.4 SEXUALLY TRANSMITTED INFECTIONS 86
9.5 SEPSIS 87
9.6 MENINGITIS 88
9.7 OTHERS 89
10 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY PANELS TYPE 91
10.1 OVERVIEW 92
10.2 RESPIRATORY PANEL 95
10.3 GI-ENTERIC PANEL 95
10.4 SEXUALLY TRANSMITTED DISEASE PANEL 96
10.5 BLOOD-SEPSIS PANEL 97
10.6 MENINGITIS PANEL 98
10.7 OTHERS 99
11 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY END USER 100
11.1 OVERVIEW 101
11.2 HOSPITALS 104
11.3 CLINICAL LABORATORIES 104
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 105
11.5 RESEARCH INSTITUTES 106
11.6 OTHERS 107
12 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET, BY REGION 108
12.1 ASIA-PACIFIC 109
12.1.1 CHINA 116
12.1.2 JAPAN 119
12.1.3 INDIA 122
12.1.4 SOUTH KOREA 125
12.1.5 AUSTRALIA 128
12.1.6 SINGAPORE 131
12.1.7 THAILAND 134
12.1.8 MALAYSIA 137
12.1.9 INDONESIA 140
12.1.10 PHILIPPINES 143
12.1.11 REST OF ASIA-PACIFIC 146
13 ASIA PACIFIC SYNDROMIC MULTIPLEX DIAGNOSTIC MARKET: COMPANY LANDSCAPE 147
13.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 147
14 SWOT ANALYSIS 148
15 COMPANY PROFILE 149
15.1 BIOFIRE DIAGNOSTICS (A SUBSIDIARY OF BIOMRIEUX SA) 149
15.1.1 COMPANY SNAPSHOT 149
15.1.2 REVENUE ANALYSIS 149
15.1.3 COMPANY SHARE ANALYSIS 150
15.1.4 PRODUCT PORTFOLIO 150
15.1.5 RECENT DEVELOPMENTS 151
15.2 F. HOFFMANN-LA ROCHE LTD 152
15.2.1 COMPANY SNAPSHOT 152
15.2.2 REVENUE ANALYSIS 152
15.2.3 COMPANY SHARE ANALYSIS 153
15.2.4 PRODUCT PORTFOLIO 153
15.2.5 RECENT DEVELOPMENT 154
15.3 LUMINEX CORPORATION. A DIASORIN COMPANY 155
15.3.1 COMPANY SNAPSHOT 155
15.3.2 RECENT FINANCIALS 155
15.3.3 COMPANY SHARE ANALYSIS 156
15.3.4 PRODUCT PORTFOLIO 156
15.3.5 RECENT DEVELOPMENT 157
15.4 CEPHEID (A SUBSIDIARY OF DANAHER) 158
15.4.1 COMPANY SNAPSHOT 158
15.4.2 RECENT FINANCIALS 158
15.4.3 COMPANY SHARE ANALYSIS 159
15.4.4 PRODUCT PORTFOLIO 159
15.4.5 RECENT DEVELOPMENTS 160
15.5 QIAGEN 161
15.5.1 COMPANY SNAPSHOT 161
15.5.2 RECENT FINANCIALS 161
15.5.3 COMPANY SHARE ANALYSIS 162
15.5.4 PRODUCT PORTFOLIO 162
15.5.5 RECENT DEVELOPMENT 162
15.6 ABBOTT 163
15.6.1 COMPANY SNAPSHOT 163
15.6.2 REVENUE ANALYSIS 163
15.6.3 PRODUCT PORTFOLIO 164
15.6.4 RECENT DEVELOPMENT 164
15.7 AKONNI BIOSYSTEMS, INC. 165
15.7.1 COMPANY SNAPSHOT 165
15.7.2 PRODUCT PORTFOLIO 165
15.7.3 RECENT DEVELOPMENT 165
15.8 APPLIED BIOCODE, INC. 166
15.8.1 COMPANY SNAPSHOT 166
15.8.2 PRODUCT PORTFOLIO 166
15.8.3 RECENT DEVELOPMENTS 167
15.9 BD 168
15.9.1 COMPANY SNAPSHOT 168
15.9.2 REVENUE ANALYSIS 168
15.9.3 PRODUCT PORTFOLIO 169
15.9.4 RECENT DEVELOPMENTS 169
15.10 BIOCARTIS 170
15.10.1 COMPANY SNAPSHOT 170
15.10.2 REVENUE ANALYSIS 170
15.10.3 PRODUCT PORTFOLIO 171
15.10.4 RECENT DEVELOPMENT 171
15.11 BIO-RAD LABORATORIES, INC. 172
15.11.1 COMPANY SNAPSHOT 172
15.11.2 REVENUE ANALYSIS 172
15.11.3 PRODUCT PORTFOLIO 173
15.11.4 RECENT DEVELOPMENT 173
15.12 BOSCH HEALTHCARE SOLUTIONS GMBH (A SUBSIDIARY OF ROBERT BOSCH GMBH) 174
15.12.1 COMPANY SNAPSHOT 174
15.12.2 REVENUE ANALYSIS 174
15.12.3 PRODUCT PORTFOLIO 175
15.12.4 RECENT DEVELOPMENT 175
15.13 CURETIS (A SUBSIDIARY OF OPGEN, INC.) 176
15.13.1 COMPANY SNAPSHOT 176
15.13.2 RECENT FINANCIALS 176
15.13.3 PRODUCT PORTFOLIO 177
15.13.4 RECENT DEVELOPMENTS 177
15.14 HOLOGIC, INC. 178
15.14.1 COMPANY SNAPSHOT 178
15.14.2 RECENT FINANCIALS 178
15.14.3 PRODUCT PORTFOLIO 179
15.14.4 RECENT DEVELOPMENT 179
15.15 MIRXES PTE LTD. 180
15.15.1 COMPANY SNAPSHOT 180
15.15.2 PRODUCT PORTFOLIO 180
15.15.3 RECENT DEVELOPMENT 180
15.16 NANMIX, INC. 181
15.16.1 COMPANY SNAPSHOT 181
15.16.2 PRODUCT PORTFOLIO 181
15.16.3 RECENT DEVELOPMENT 181
15.17 PROMINEX INC. 182
15.17.1 COMPANY SNAPSHOT 182
15.17.2 PRODUCT PORTFOLIO 182
15.17.3 RECENT DEVELOPMENT 182
15.18 QUANTUMDX GROUP LTD. 183
15.18.1 COMPANY SNAPSHOT 183
15.18.2 PRODUCT PORTFOLIO 183
15.18.3 RECENT DEVELOPMENTS 183
15.19 SEEGENE INC. 184
15.19.1 COMPANY SNAPSHOT 184
15.19.2 REVENUE ANALYSIS 184
15.19.3 PRODUCT PORTFOLIO 185
15.19.4 RECENT DEVELOPMENTS 188
15.20 SIEMENS HEALTHCARE GMBH 189
15.20.1 COMPANY SNAPSHOT 189
15.20.2 RECENT FINANCIALS 189
15.20.3 PRODUCT PORTFOLIO 190
15.20.4 RECENT DEVELOPMENT 190
15.21 THERMOFISHER SCIENTIFIC INC. 191
15.21.1 COMPANY SNAPSHOT 191
15.21.2 RECENT FINANCIALS 191
15.21.3 PRODUCT PORTFOLIO 192
15.21.4 RECENT DEVELOPMENT 192
16 QUESTIONNAIRE 193
17 RELATED REPORTS 196
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
